Retrospective Study
Copyright ©The Author(s) 2019.
World J Clin Cases. Nov 6, 2019; 7(21): 3419-3435
Published online Nov 6, 2019. doi: 10.12998/wjcc.v7.i21.3419
Table 2 Preoperative analysis of overall survival
Univariate analysis
Multivariate analysis
VariableHR (95%CI)P valueHR (95%CI)P value
Preoperative tumor size(cm)< 0.0010.012
< 5RefRef
≥ 52.953 (2.227-3.915)1.480 (1.090-2.010)
Preoperative N stage< 0.001< 0.001
N0RefRef
N+3.219 (2.428-4.268)2.069 (1.536-2.787)
Preoperative T stage< 0.001< 0.001
T1-3RefRef
T44.550 (3.132-6.609)2.767 (1.846-4.148)
Preoperative CA19-9 (U/mL)< 0.0010.003
< 33.35RefRef
≥ 33.352.250 (1.750-2.894)1.569 (1.166-2.110)
ASA score< 0.001< 0.001
1RefRef
21.725 (1.299-2.289)1.675 (1.257-2.230)
33.805 (2.677-5.409)3.257 (2.271-4.670)
3- to 6-mo weight loss< 0.0010.036
NoRefRef
Yes1.588 (1.231-2.049)1.316 (1.019-1.701)
Age (yr)0.008
< 65Ref
≥ 651.412 (1.095-1.821)
Gender0.318
FemaleRef
Male1.178 (0.854-1.625)
BMI (kg/m2)0.473
<25Ref
≥ 250.875 (0.609-1.259)
Accompanying disease0.673
NoRef
Yes0.944 (0.724-1.232)
History of abdominal surgery0.704
NoRef
Yes1.146 (0.566-2.321)
Preoperative Charlson score
0Ref
1-21.007 (0.768-1.322)0.959
≥ 32.202 (0.973-4.982)0.058
Preoperative CEA (µg/mL)<0.001
< 4Ref
≥ 41.673 (1.294-2.164)
HB, g/L0.265
≥ 9.0Ref
< 9.01.239 (0.850-1.808)
ALB, g/L0.014
≥ 35Ref
< 351.410 (1.072-1.854)
Fibrinogen, g/L0.003
< 4Ref
≥ 41.471 (1.137-1.904)